TERIL (carbamazepine) by Teva is cytochrome p450 3a4 inducers [moa]. Approved for the treatment of the pain associated with true trigeminal neuralgia, epilepsy. First approved in 2003.
Drug data last refreshed 1w ago
Cytochrome P450 3A4 Inducers
Drug-drug Interaction Trial of AP31969 and Carbamazepine or Itraconazole
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
Use of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of Trapeziometacarpal Osteoarthritis
A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults
To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants
Worked on TERIL at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.